FluoroPharma Medical, Inc. (FPMI)
Key Executives
Name | Title | Pay | Exercised | Year Born |
---|---|---|---|---|
Dr. Thomas H. Tulip Ph.D. | CEO, President & Director | 320k | -- | 1953 |
Ms. Tamara Rhein | Chief Financial Officer | 130k | -- | 1972 |
Mr. Edward L. Lyons Jr. | Vice President of Development | -- | -- | -- |
FluoroPharma Medical, Inc.
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 4
Description
FluoroPharma Medical, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of molecular imaging pharmaceuticals with initial applications in the area of cardiology in the United States. Its product candidates include BFPET, an imaging agent that has completed a Phase I clinical trial in stress-testing for patients with presumptive or proven coronary artery disease (CAD); and CardioPET, a molecular imaging agent, which is in Phase IIa clinical trial to assess myocardial blood flow and metabolism in patients with CAD. The company has license agreements with Massachusetts General Hospital and Sinotau USA; and clinical research agreements with Pharmaceutical Product Development, LLC, as well as Cardiovascular Imaging Technologies. FluoroPharma Medical, Inc. was founded in 2003 and is headquartered in Montclair, New Jersey.
Corporate Governance
Recent Events
- Oct 13, 202215-15D: Notice of suspension of duty to file reports pursuant to Section 13 and 15(d) of the ActSee Full Filing
- Jun 23, 20228-K: Corporate Changes & Voting MattersSee Full Filing
Upcoming Events
Upcoming Events Information Not Available